INNOVATIVE PROCEDURE ADDRESSES CANCER OF THE PERITONEAL CAVITY
Article provided by Cleveland Clinic, USA
C
ancer of the peritoneal cavity that originates from primary colorectal cancer, ovarian cancer, gastric
cancer, appendiceal cancer, mesothelioma and peritoneal carcinomatosis has been virtually incurable. For patients diagnosed with stage IV peritoneal carcinomatosis, survival is approximately four months. Surgical therapy is producing
promising results for some patients. Cytoreductive (debulking) Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are aggressive treatments that have shown to increase life expectancy for well-selected patients with advanced abdominal cancers. “Recently, a series of research studies
have shown clear benefits for patients who have undergone CS and HIPEC surgeries,” says Cleveland Clinic hepato- pancreato-biliary and transplant surgeon Sricharan Chalikonda, MD, who performs approximately four CS and HIPEC surgeries every month. “For the right patients, we are starting to see survival rates increase by years.”
CS is a complicated surgical procedure that takes up to 10 to 12 hours to
54
www.lifesciencesmagazines.com
perform. It involves the destruction and/ or resection of visible tumors within the peritoneal cavity. Depending on the size and location of the tumors, the procedure also may involve the partial resection of various viscera, such as the small bowel, large bowel, spleen and uterus. Removing all visible tumors is crucial to the patient’s prognosis for long term survival. The patient’s survival also depends on the volume of tumors within the abdomen and the aggressiveness of the carcinoma. The patient’s survival outlook decreases when all tumors cannot be eradicated or resected, unless they are less than 2.5 millimeters. HIPEC facilitates the destruction of very
small tumors that cannot be seen by the surgeon. HIPEC also eliminates cancer cells that may be hiding or those that may have been released during resections of visible tumors or when portions of visceral organs have been removed. The HIPEC procedure involves placing special catheters in the patient’s abdomen. Once the chemotherapy agent is heated to 42 degrees Celsius, it is distributed into the abdomen through the catheters for 100 minutes.
“HIPEC enables us to deliver higher
concentrations of the chemotherapy agent into the perineoal cavity, which facilitates the destruction of remaining cancer cells,” explains Cleveland Clinic gynecologic oncologist Pedro Escobar, MD, who operates with Dr. Chalikonda on gyn cases. HIPEC causes fewer side effects than IV chemotherapy because of the peritoneal plasma barrier, which prevents the high concentrations of the chemotherapy solution from invading the blood stream. Patients who may be candidates for
CS and HIPEC are those with Stage IV cancer that is confined to the abdomen with no evidence of hematagenous spread of the disease. Other factors include comorbidities, the type of cancer, surgical history and the patient’s overall physical strength to withstand the CS and HIPEC procedures. ■
AH
MORE INFO: To make a referral or for more information, please contact Dr. Escobar at +1 216.445.8486 or Dr. Chalikonda at +1 216.445.0053.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64